WHO Approves Trials of Two Vaccines as DRC Ebola Outbreak Spreads
publishers 145articles 249first reported 1 Oct, 16:11 UTCdeveloping since 2 Oct · 44 editions
The World Health Organization has approved clinical trials of two vaccines designed to combat the Bundibugyo strain of Ebola amid a rapidly growing outbreak centered in the Democratic Republic of the Congo.
WHO expert groups recommended adding the two vaccine candidates to the response after the strain killed more than 5,300 people, mostly in the DRC, since the outbreak was declared in May, Al Jazeera reported. Earlier DRC Health Ministry data recorded 5,026 deaths among 10,351 infections, a fatality rate of nearly 50%. The Africa Centres for Disease Control and Prevention later reported 10,444 confirmed cases.
The trials are being led by the DRC’s National Institute for Biomedical Research with support from the WHO and other partners. The vaccines specifically target the Bundibugyo strain. Results are expected in early 2027. An earlier trial used Ervebo, a vaccine approved for the Zaire strain but not designed for Bundibugyo.
Cases have also been reported outside the DRC, including nine in Kenya, with two deaths, and one in Nigeria, according to Al Jazeera’s account of health-agency data.
A British doctor infected while treating Ebola patients in the DRC has been evacuated to London and is receiving specialist care in a high-level isolation unit at the Royal Free Hospital. UK health authorities said established infection-control measures are in place and the risk to the wider public remains low.
HOW THIS STORY WAS MADE
Written from 8 articles, 3 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 840 h after the record first saw the story; the editor revised it.
- Publishers
- 145
- Source articles
- 249
- Given to the writer
- 8, 3 with the article's own text
- Independent newsrooms
- 8
- This version written
- 840 h after the record first saw the story
- Second model (editor)
- revised
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and changed it before publication. Struck words were in the draft; underlined words are its corrections.
WHAT IT FLAGGED editor revise: Delete the unsupported claim that both vaccine candidates share the same developers. - "The vaccines, developed by the University of Oxford with the Serum Institute of India and Moderna, specifically target the Bundibugyo strain.": The source attributes that development partnership only to a singular vaccine and does not establish that both candidates were jointly developed by all three organizations.
THE DRAFT AND THE CHANGES
WHO Approves Trials of Two Vaccines as DRC Ebola Outbreak Spreads
The World Health Organization has approved clinical trials of two vaccines designed to combat the Bundibugyo strain of Ebola amid a rapidly growing outbreak centered in the Democratic Republic of the Congo.
WHO expert groups recommended adding the two vaccine candidates to the response after the strain killed more than 5,300 people, mostly in the DRC, since the outbreak was declared in May, Al Jazeera reported. Earlier DRC Health Ministry data recorded 5,026 deaths among 10,351 infections, a fatality rate of nearly 50%. The Africa Centres for Disease Control and Prevention later reported 10,444 confirmed cases.
The trials are being led by the DRC’s National Institute for Biomedical Research with support from the WHO and other partners. The vaccines, developed by the University of Oxford with the Serum Institute of India and Moderna,vaccines specifically target the Bundibugyo strain. Results are expected in early 2027. An earlier trial used Ervebo, a vaccine approved for the Zaire strain but not designed for Bundibugyo.
Cases have also been reported outside the DRC, including nine in Kenya, with two deaths, and one in Nigeria, according to Al Jazeera’s account of health-agency data.
A British doctor infected while treating Ebola patients in the DRC has been evacuated to London and is receiving specialist care in a high-level isolation unit at the Royal Free Hospital. UK health authorities said established infection-control measures are in place and the risk to the wider public remains low.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →